Doug Drysdale
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psychedelics and 5-HT2A agonists show varying anti-inflammatory effects unrelated to their behavioral impact. Research identifies cellular mechanisms and aims to develop new compounds with targeted therapeutic properties.
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
Psychedelic compounds show promise for treating neuropsychiatric disorders, but limited patient access is a challenge. Non-hallucinogenic psychedelics, or neuroplastogens, are emerging as a potential solution to address concerns.
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Entheogens are being used in traditional Indigenous medicine practices for therapeutic purposes. Indigenous initiatives are creating intercultural clinics to offer entheogen-assisted treatments for substance use disorders and mental health challenges.
Anja Loizaga-Velder
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.